nizatidine


Also found in: Dictionary, Wikipedia.
Related to nizatidine: omeprazole

nizatidine

 [nĭ-za´tĭ-dēn]
a histamine H2 receptor antagonist, used to inhibit gastric acid secretion in the treatment of gastric and duodenal ulcer, gastroesophageal reflux disease, and conditions that cause gastric hypersecretion; administered orally.

nizatidine

Apo-Nizatidine, Axid, Axid AR, Dom-Nizatidine, Gen-Nizatidine, Novo-Nizatidine, PHL-Nizatidine, PMS-Nizatidine, Zinga (UK)

Pharmacologic class: Histamine2 (H2)-receptor antagonist

Therapeutic class: Antiulcer drug

Pregnancy risk category B

Action

Inhibits histamine action at H2-receptor sites in gastric parietal cells, reducing gastric acid secretion and pepsin production

Availability

Capsules: 150 mg, 300 mg

Oral solution: 15 mg/ml

Tablets: 75 mg

Indications and dosages

Active duodenal ulcer Adults: 300 mg P.O. daily at bedtime or 150 mg b.i.d. for up to 8 weeks

Maintenance of healed duodenal ulcers

Adults and children ages 12 and older: 150 mg P.O. daily at bedtime for up to 1 year

Esophagitis and associated heartburn caused by gastroesophageal reflux disease (GERD)

Adults: 150 mg P.O. b.i.d. for up to 12 weeks

Active benign gastric ulcer Adults: 150 mg P.O. b.i.d. or 300 mg P.O. once daily at bedtime

Erosive esophagitis; GERD

Children ages 12 and older: 150 mg P.O. b.i.d. for up to 8 weeks

Dosage adjustment

• Moderate to severe renal impairment

• Elderly patients

Contraindications

• Hypersensitivity to drug or other H2-receptor antagonists

Precautions

Use cautiously in:

• mild renal impairment

• elderly patients

• pregnant or breastfeeding patients

• children younger than age 12 (safety and efficacy not established).

Administration

• Give with or without food.

• If patient is to take drug twice daily, give one dose in morning and one at bedtime.

Adverse reactions

CNS: dizziness, drowsiness, headache, anxiety, nervousness, insomnia, abnormal dreams, asthenia

CV: chest pain

EENT: amblyopia, sinusitis, rhinitis, pharyngitis

GI: nausea, vomiting, diarrhea, constipation, dyspepsia, abdominal pain, flatulence, anorexia, dry mouth

Hematologic: anemia

Musculoskeletal: back pain, myalgia

Respiratory: cough

Skin: rash, pruritus

Other: tooth disorder, infection, fever, pain

Interactions

Drug-drug. Salicylates (high doses): increased salicylate blood level

Drug-diagnostic tests. Alanine amino-transferase, alkaline phosphatase, aspartate aminotransferase: elevated levels

Urobilinogen tests using Multistix: false-positive result

Drug-herbs. Pennyroyal: altered rate of herbal metabolite formation

Patient monitoring

• Monitor liver and renal function tests.

• Check temperature; watch for fever and other signs and symptoms of infection.

Patient teaching

• Advise patient to take once-daily dose at bedtime with or without food, or twice-daily doses in morning and at bedtime.

• Instruct patient to take exactly as prescribed. Caution him not to take other OTC drugs (especially aspirin).

• Tell patient to report signs and symptoms of infection.

• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

nizatidine

(nī-zăt′ĭ-dēn′)
n.
A histamine receptor antagonist, C12H21N5O2S2, that inhibits the secretion of gastric acid and is used to treat duodenal and gastric ulcers and gastroesophageal reflux disease.

nizatidine

A H2-receptor antagonist used to treat peptic ulcer disease.
 
Adverse reactions
Diarrhoea, headache, drowsiness, fatigue, muscle pain, constipation, confusion, agranulocytosis, gynaecomastia, impotence, allergic reactions, tachycardia, arrhythmias, interstitial nephritis.

nizatidine

Axid® Therapeutics An H2-receptor antagonist used to treat peptic ulcer disease Adverse reactions Diarrhea, headache, drowsiness, fatigue, muscle pain, constipation, confusion, agranulocytosis, gynecomastia, impotence, allergic reactions, tachycardia, arrhythmias, interstitial nephritis, etc. See Histamine receptor antagonists.

nizatidine

An H2 RECEPTOR ANTAGONIST drug used to prevent and treat peptic ulcers. Brand names are Axid and Zinga.
References in periodicals archive ?
The former includes agents such as omeprazole and lansoprazole, and the latter includes drugs such as famotidine, nizatidine, ranitidine, and cimetidine.
At the end of the week, among 208 evaluable patients, 14% of those treated with nizatidine and 40% of those treated with pantoprazole had complete relief of their heartburn.
* Histamine-2 receptor antagonists (H2 blockers), which include over-the-counter and prescription cimetidine (Tagamet), famotidine (Pepcid), nizatidine (Axid) and ranitidine (Zantac).
Searle & Co.'s Cytotec), nizatidine (Eli Lilly and Co.'s Axid), lisinopril (Merck & Co.'s Prinivil) and lisinopril and HCTZ (Merck's Prinzide).
Placebo-controlled trial of cisapride and nizatidine in unselected patients with functional dyspepsia.
The new generic drugs Mylan Pharmaceuticals has been given FDA approval for include nizatidine capsules, tramadol HCl tablets, lisinopril tablets, lisinopril and hydrochlorothiazide tablets, a variety of levothyroxine sodium tablets, buspirone HCl tablets, ketoprofen capsules, metformin HCl tablets and fluoxetine HCl capsules.
Three classes of drugs are currently used: the histamine-receptor antagonists (eg, ranitidine, famotidine, nizatidine); the gastric acid-pump inhibitor (omeprazole); and the prostaglandin analogue (misoprostol).
H2 receptor antagonists (H2 blockers), including cimetidine (Tagamet), famotidine (Pepcid), nizatidine (Axid) and ranitidine (Zantac).
Pharmacologic Therapy for Gastroesophageal Reflux Disease Barrier agents Alginic acid Antacids Anti-secretory agents [H.sub.2]-receptor antagonists Cimetidine Ranitidine Famotidine Nizatidine Omeprazole Prokinetic agents Metoclopramide Bethanechol Cisapride (*) Domperidone (*) Sucralfate (*) Not yet available in the United States.
Other abbreviated new drug applications (ANDAs) from Mylan expected to be approved by the FDA and launched in fiscal 2003 are Fluoxetine, Nizatidine, Lisinopril, Tamoxefin, Ciprofloxacin and Loratadine.
dose form (Glaxo Wellcome Inc.'s Zantac 75), buspirone hydrochloride (Bristol-Myers Squibb's Buspar) and nizatidine capsules USP in strengths of 150 mg.